Cardiometabolic Health Congress

NOVEMBER 25, 2024

Diabetes Management: Gain insights into precision medicine, advanced insulin therapies, and continuous glucose monitoring (CGM) for cardiovascular risk assessment. Dyslipidemia, Atherosclerosis & Thrombosis: Explore non-statin therapies, strategies for managing hypertriglyceridemia, and new guidance on lipoprotein(a) management.

CME 52

CME Obesity Certification Education 52

Dr. Smith's ECG Blog

NOVEMBER 15, 2023

MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection; myocardial disorders, including myocarditis, takotsubo cardiomyopathy, and other cardiomyopathies. This is in spite of the known proclivity of tighter stenoses to thrombose.

Coronary Angiogram 109

Coronary Angiogram Plaque Thrombosis STEMI 109

Open Heart

NOVEMBER 28, 2023

Objective Literature supports associations between common respiratory tract infections (RTIs) and risk of cardiovascular diseases, yet the importance of RTIs for cardiovascular risk management remains less understood. to 44.9)) and deep venous thrombosis (7.8 (4.3 to 11.0)), stroke (3.5 (1.2 95% CI 1.8 95% CI 1.1

Myocardial Infarction 52

Myocardial Infarction COVID-19 Cardiovascular Disease Thrombosis 52

Open Heart

JUNE 9, 2023

All the patients were observed during their hospital stay for postprocedure in-hospital morbidity (pump failure, contrast-induced nephropathy, major bleeding, cerebrovascular accident/stroke, access site complications or stent thrombosis) and mortality. The mean BMI was 27.48±4.93 kg/m 2 and 23.2% (255) were categorised as obese.

Obesity 40

Obesity BMI Hospital Thrombosis 40

Stroke Journal

JANUARY 30, 2025

Elevated levels of Lp(a) are an independent and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms associated with increased atherogenesis, inflammation, and thrombosis. Lipoprotein (a) [Lp(a)] is a type of lipoprotein that is genetically inherited.

Stroke 40

Stroke Strokes Academic Risk Factors 40

Cardiometabolic Health Congress

AUGUST 23, 2024

As a leading cause of cardiovascular disease, dyslipidemia also has far-reaching implications for cognitive health, underscoring its broad impact.

Dementia 52

Dementia Cholesterol Risk Factors CME 52

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

MINOCA may be due to: coronary spasm, coronary microvascular dysfunction, plaque disruption, spontaneous coronary thrombosis/emboli , and coronary dissection. link] We know that most type 1 acute MI due to plaque rupture and thrombosis occurs in lesions that are less than 50% (see Libby reference). From Gue at al.

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52

DAIC

JANUARY 23, 2024

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

Journal of the American Heart Association

JANUARY 31, 2024

BackgroundEffective therapies for reducing cardiovascular disease (CVD) risk in people with elevated lipoprotein(a) are lacking, especially for primary prevention. Methods and ResultsWe used data from the MESA (Multi‐Ethnic Study of Atherosclerosis), a prospective cohort study of individuals free of baseline cardiovascular disease.

Atherosclerosis 75

Atherosclerosis Risk Factors Myocardial Infarction Cardiovascular Disease 75

Heart 2023 Conference

APRIL 20, 2022

Avocado consumption of at least two servings per week is linked to a lower risk of cardiovascular disease. Harvard University Heart Letter) A clinical polygenic risk score test for diseases ranging from atrial fibrillation (AFib) to breast cancer was piloted by scientists.

Pulmonary 52

Pulmonary Hypertension AFIB COVID-19 52

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). The primary non-inferiority endpoint was MACCE (a composite of cardiac death, MI, ischaemic stroke, stent thrombosis, or target vessel revascularisation).

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

DAIC

MAY 7, 2024

About Pulmonary Embolism PE is often caused by blood clots in the legs, otherwise known as deep vein thrombosis, that travel through the veins and into the lungs. “Evaluating care disparities in real clinical practices is key to addressing the existing barrier and improving patient outcomes,” Parikh added.

Embolism 122

Embolism Pulmonary Blood Clot Interventional Cardiology 122

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2024

Extracellular vesicles (EVs) are nanosized particles secreted by cells that play crucial roles in intercellular communication, especially in the context of cardiovascular diseases (CVDs). For example, proteins involved in inflammation, thrombosis, and cardiac remodeling have been identified as potential therapeutic targets.

Cardiovascular Disease 93

Cardiovascular Disease Thrombosis Physiology Research 93

Frontiers in Cardiovascular Medicine

NOVEMBER 25, 2024

Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary heart disease, cerebrovascular disease (e.g., stroke), peripheral arterial disease, congenital heart anomalies, deep vein thrombosis, and pulmonary embolism.

Cardiovascular Disease 59

Cardiovascular Disease Peripheral Arterial Disease Cerebrovascular Disease Thrombosis 59

Frontiers in Cardiovascular Medicine

JANUARY 8, 2025

ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions.

Cerebrovascular Disease 52

Cerebrovascular Disease Cardiovascular Disease Myocardial Infarction Angina 52

DAIC

JANUARY 11, 2024

Researchers analyze primary and secondary cardiovascular outcomes in 132,784 inpatients with COVID-19 (October 8, 2020 to September 30, 2021) and 31,173 inpatients with non-COVID-19 pneumonia (January 1, 2019 to December 31, 2019) in Korea. The results indicate a lower risk of cardiovascular disease in COVID-19 patients.

COVID-19 103

COVID-19 Hospital Thrombosis Inpatient 103